Lo.G protects medicines in transit

Published: 27-May-2010

LIVE FROM TOTAL PROCESS & PACKAGING

Plastique, a UK-based plastics thermoforming firm, is offering protective packaging for fragile items such as medicines.

The Lo.G protects products in transit with the help of a patented 360° impact absorbing buffer system, which ensures that contents are centrally cushioned and protected.

Lo.G packs are made from recycled HDPE plastic. As a nesting product, they offer weight, space and energy savings throughout the supply chain, from warehousing to point-of-sale, when compared with EPS block or foam protective packaging.

Plastique of Tunbridge Wells, Kent offers the Lo.G packaging in single piece ‘wrap-round and lock’ boxes or end cap formats to suit a variety of products.

The company also unveiled Paperlite rPET material developed by Flextrus of Sweden, which is an alternative to thermoformed plastic trays.

According to Plastique’s sales and marketing executive, Daryl Thompson, PaperLite can be used for packaging drugs or medical devices. The material, which looks and feels like paper, is based on FibreForm from Billerud and will run on existing form fill and seal lines. It is also FSC certified and has environmental advantages over thermoformed plastic trays.

PaperLite won the Packaging Innovation Award 2009 at the Scanpack exhibition in Gothenburg.

See more

You may also like

Research & Development

Med Uni Graz researchers present a new approach to targeted therapy for leukaemia

Read more
Acute myeloid leukaemia (AML) is a cancer of the haematopoietic cells that causes the uncontrolled proliferation of certain immature blood cells

Trending Articles

  1. Manufacturing Chemist Stand Side with GEA and Hovione We discover what exhibitors at CPHI 2025 are showcasing LIVE!
  2. Thermo Fisher Scientific Expands Gibco Bacto portfolio Its next-generation, chemically defined media will boost E. coli biomanufacturing productivity, helping innovators scale plasmid DNA and protein production with confidence
  3. You need to be a subscriber to read this article.
    Click here to find out more.
    Integrating responsible AI into ESG strategies Today, artificial intelligence (AI) is changing the way businesses operate, but there’s no denying that it presents both opportunities and risks
  4. FDA considers black box warning for COVID-19 vaccines amid internal disputes The US FDA is reportedly weighing a black box warning for COVID-19 vaccines — a move that has alarmed public health leaders and vaccine manufacturers, who say no new safety signals support such action
  5. Romaco Holding GmbH Romaco is a leading international supplier of machinery and integrated system solutions for the development, production and packaging of pharmaceuticals, nutraceuticals, food, cosmetic and chemical products. All from a single source.

Upcoming event

From powder to granules: a deep dive into wet granulation methods

14 January 2026 | Virtual See all

You may also like

Research & Development

Med Uni Graz researchers present a new approach to targeted therapy for leukaemia

Acute myeloid leukaemia (AML) is a cancer of the haematopoietic cells that causes the uncontrolled proliferation of certain immature blood cells
Manufacturing

When science meets security: the future of small molecule outsourcing

Looking across 2025 and into 2026, chemical and pharmaceutical manufacturing is navigating a period of rapid transition, with trends emerging that will influence competitiveness for years to come
Digital

Pharma in 2025–2026: AI, China and the new era of drug development

In 2025, the pace of change throughout chemical and pharmaceutical manufacturing is accelerating, creating a complex mix of emerging opportunities and structural challenges that will define the year ahead
Research & Development

Research shows that Pepaxti is effective in high-risk myeloma

Oncopeptides announces new research demonstrating that Pepaxti (melflufen) maintains its anti-myeloma activity in patients with high-risk genetic features, including deletion 17p (del(17p)) and TP53 mutations
Research & Development

Biologics at a turning point: complexity, AI and the road to 2026

Despite rapid change, the growing complexity of biologics and the rise of AI-driven design are reinforcing the increasing need for deep scientific expertise and innovation leadership, says Campbell Bunce (CB), Chief Scientific Officer at Abzena
Distribution

Yusen Logistics Group completes acquisition of Walden Health, strengthening global healthcare logistics capabilities

Yusen Logistics Global Management is pleased to announce that Yusen Logistics (Europe) BV, an overseas subsidiary of Yusen Logistics Group, has completed the acquisition of the Walden Group subsidiaries Movianto, Eurotranspharma, Transpharma International and Walden Digital
Regulatory

Grifols receives US FDA approval for new fibrinogen concentrate: FESILTY (fibrinogen, human-chmt)

The fibrinogen concentrate complements Grifols’ bleeding management portfolio, expanding therapeutic options for patients
Subscribe now